In Vitro: EB-3D displays (0-100 μM; 72 hours) excellent antiproliferative activity against a wide cohort of T-leukemic cell lines, with GI GI50s 13 values in the nanomolar range. EB-3D (1.25-5μM; 24 hours) induced apoptosis in leukemia cell lines. EB-3D (0.5-1 μM; 24 hours) induces a G0/G1 arrest that lead to apoptosis. EB-3D (0.3 μM; 48 hours) shows a first spike of activation of AMPKα after 30 minutes and a later increase in the phosphorylation of T172. EB-3D (1-40 μM; 48 hours) inhibits cell growth in HepG2 cells with a GI50 of 14.55 μM. EB-3D induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells.
In Vivo: EB-3D (1 mg/kg; i.p.; every other day) impairs mammary tumor growth in syngeneic orthotopic E0771-C57BL/6 mouse model. EB-3D (2.5 mg/kg; every other day for 4 weeks) shows a reduction of the number of spontaneous lung macro- and micrometastasis.